Select Page

Articles

AUGMENTING NATURAL IMMUNITY IN TRIPLE NEGATIVE BREAST CANCER  BASED ON CYTOKINE AND HORMONAL RECEPTOR ANALYSIS IN-VITRO

AUGMENTING NATURAL IMMUNITY IN TRIPLE NEGATIVE BREAST CANCER BASED ON CYTOKINE AND HORMONAL RECEPTOR ANALYSIS IN-VITRO

ABSTRACT: (532)
Submitted to:  Journal of Medical Hypothesis:

SUBTITLE:
Androgenic-Anabolic Steroids (AAS)  can Stimulated Immune Recovery In Triple Negative Breast Cancer After Chemotherapy and Radiation

INTRODUCTION:

The complex association of endocrine ablation and breast cancer (BC) was discovered in 1896 when Beatson4 revealed that oophorectomy on an advanced cancer patient led to a pronounced and marked response.

 

The presumption that estradiol was linked to breast cancer was strongly influenced in 1958 by the discovery of the estrogen receptor (ER) by E.V. Jensen5; subsequent studies showed estrogen (E2) is implicated in breast cancer pathogenesis and nurtures the surge in Estrogen Receptors expressing breast cancer cells.5
Based on that presumption, two medications have become standard in the treatment/ prevention of recurrence for early estrogen receptor positive breast cancer:  anastrozole and tamoxifen. Both are not applicable to triple negative breast cancer. Both have about a 70% initial response and many hosts develop resistance predating cancer remission.